95.24 0.00 (0.00%)
After hours: 4:44PM EDT
|Bid||95.01 x 900|
|Ask||95.73 x 1300|
|Day's Range||95.19 - 96.02|
|52 Week Range||58.59 - 97.07|
|Beta (3Y Monthly)||2.01|
|PE Ratio (TTM)||14.51|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
An IPO that happened on Thursday, a filing for another one, and more than $600 million in funding tops the Bay Area's venture news heading into the holiday weekend.
Magnetar Capital is an Evanston, Illinois-based multi-strategy asset manager that was founded in 2005 by Alec Litowitz and Ross Laser, who previously worked at Citadel LLC and Glenwood Capital Partners, respectively. The fund was launched with $1.8 billion, which represented one of the biggest hedge fund initial capitals at the time. At the very beginning, […]
Stock investors looking for a way to outperform amid the trade war's major upheaval should look at Goldman Sachs' Hedge Funds VIP list.
Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
Ted Samuels paid $236,440 for 5,000 shares last week. It’s the first open-market purchase of Bristol-Myers stock by an insider in a year.
For these mental hacks, David Gardner tapped the wisdom of four authors and one alien hive mind. For the stocks, he looked to the Information Age for inspiration.
While value investors continue to read through Seth Klarman (Trades, Portfolio)'s most recent partnership letter, others are tracking his latest filings to see what the guru has deemed worthy of buying. Warning! GuruFocus has detected 3 Warning Sign with CDAY.
Bristol-Myers Squibb's growth prospects following the planned acquisition of Celgene are a cause of concern, Toung said in a Friday downgrade note. Revlimid is Celgene's best-selling multiple myeloma drug and showed 15-percent year-over-year growth to $2.58 billion in the first quarter of 2019. It fetched roughly 64 percent of the company's revenues.
A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst.
The latest round of 13F filings from institutional investors were out this week, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling. Takeaways ...
Carlson Capital is a Dallas, Texas-based multi-strategy alternative hedge fund that provides additional offices in Houston, New York City, Palm Beach Gardens, Greenwich, and London. It was founded by Clint Carlson back in 1993 and grew big since then, now managing more than $7 billion in hedge fund and CLO assets. Prior to launching his […]
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.